Cargando…
Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330011/ https://www.ncbi.nlm.nih.gov/pubmed/34324409 http://dx.doi.org/10.1080/21645515.2021.1953344 |
_version_ | 1783732613635112960 |
---|---|
author | Soysal, Ahmet Gönüllü, Erdem Karabayır, Nalan Alan, Servet Atıcı, Serkan Yıldız, İsmail Engin, Havva Çivilibal, Mahmut Karaböcüoğlu, Metin |
author_facet | Soysal, Ahmet Gönüllü, Erdem Karabayır, Nalan Alan, Servet Atıcı, Serkan Yıldız, İsmail Engin, Havva Çivilibal, Mahmut Karaböcüoğlu, Metin |
author_sort | Soysal, Ahmet |
collection | PubMed |
description | The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals. |
format | Online Article Text |
id | pubmed-8330011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-83300112021-08-03 Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers Soysal, Ahmet Gönüllü, Erdem Karabayır, Nalan Alan, Servet Atıcı, Serkan Yıldız, İsmail Engin, Havva Çivilibal, Mahmut Karaböcüoğlu, Metin Hum Vaccin Immunother Research Paper The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals. Taylor & Francis 2021-07-29 /pmc/articles/PMC8330011/ /pubmed/34324409 http://dx.doi.org/10.1080/21645515.2021.1953344 Text en © 2021 Taylor & Francis Group, LLC |
spellingShingle | Research Paper Soysal, Ahmet Gönüllü, Erdem Karabayır, Nalan Alan, Servet Atıcı, Serkan Yıldız, İsmail Engin, Havva Çivilibal, Mahmut Karaböcüoğlu, Metin Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title | Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title_full | Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title_fullStr | Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title_full_unstemmed | Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title_short | Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers |
title_sort | comparison of immunogenicity and reactogenicity of inactivated sars-cov-2 vaccine (coronavac) in previously sars-cov-2 infected and uninfected health care workers |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330011/ https://www.ncbi.nlm.nih.gov/pubmed/34324409 http://dx.doi.org/10.1080/21645515.2021.1953344 |
work_keys_str_mv | AT soysalahmet comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT gonulluerdem comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT karabayırnalan comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT alanservet comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT atıcıserkan comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT yıldızismail comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT enginhavva comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT civilibalmahmut comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers AT karabocuoglumetin comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers |